VEGF gene delivery to myocardium: deleterious effects of unregulated expression.

By R. J. Lee, M. Springer, W. Blanco-Bose, R. Shaw, P. Ursell, Helen M. Blau. Circulation, 2000

738 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “The ultrasonic microbubble destruction induced microvessel disruptions which allowed intravascular constituents to be transported into the endothelium and interstitium of ultrasound-exposed tissues [181–183].”
Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. (2002, background): “2H, 3I), rather than a hierarchical vascular tree (Carmeliet 2000; Lee et al. 2000; Sundberg et al. 2001), most likely because a saturating growth signal is provided in the absence of proper positional information.”
Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. (2002, result): “This finding contradicts previous reports indicating that high doses of VEGF lead to hemangioma (18, 19) or disruption in embryonic myocardium development (20).”
Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. (2004, background): “However, exogenous administration of VEGF results in leaky, malformed vessels which has raised concerns regarding its therapeutic usefulness.(13,14) Recent studies have established that angiogenesis is not the sole mechanism by which new vessels are formed.”